In order to request this CME/CE activity for your center, please contact Samantha Zelasko at SZelasko@gotoper.com

Sessions:

May 24th, 10:00 am - 11:00 am CT

Register Here

May 29th, 10:00 am - 11:00 am CT

Register Here

The progress in treating patients with chronic myeloid leukemia (CML) over the last 20 years is unmatched by any other malignancy. Illustrating the transformative impact of tyrosine kinase inhibitor (TKI) therapy, a patient diagnosed with CML today who is well managed and adherent to treatment has expected survival approaching that of the general population. Despite the tremendous progress, care for patients with CML remains challenging. Approximately half of the patients receiving therapy with a first-generation BCR-ABL TKI have suboptimal outcomes. Patients may lose complete cytogenetic response or experience treatment-related adverse side effects leading to medication non-adherence or treatment discontinuation. Making individual patient-centered treatment decisions requires acute understanding and application of currently available data including differentiation of the TKIs currently approved by the US FDA for the treatment of CML.

Oncology Best Practice™: Multidisciplinary Strategies for Improving Outcomes in CML from Frontline Care… and Beyond! is specifically designed to update oncology providers in community care centers utilizing an intimate small group settings. The format provides a collegial atmosphere allowing for open, fluid discussions with expert thought leaders addressing the application of current data and pressing clinical challenges faced by participants.

• Get the most recent data from clinical trials evaluating care for patients with CML
• Hear expert perspectives on management strategies for patients undergoing TKI therapy for CML
• Discuss steps to take when patients are not meeting milestones
• Learn multidisciplinary strategies to mitigate and manage TKI-associated adverse events
• Differentiate between current and emerging treatments for patients with CML

This activity is supported by an educational grant Novartis Pharmaceuticals Corporation.

This educational activity is directed toward hematologists/oncologists, pediatric hematologists, NP/PAs, pharmacists, payers, and nurses.

Upon completion of this activity, participants will be able to:

• Review efficacy and safety of current and emerging first-line strategies for patients with CML
• Determine trials that are key to treatment approaches for patients with CML across multiple lines of care
• Evaluate proactive multidisciplinary strategies to mitigate, monitor, and manage adverse events, thereby facilitating therapeutics adherence in patients with CML

Physicians’ Education Resource^®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource^®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.

Elias Jabbour, MD
Professor, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant/Research Support: AbbVie, Adaptive Biotechnologies, Amgen, Bristol Myers Squibb, Novartis Pharmaceuticals, Pfizer, Spectrum Pharmaceuticals, Takeda Pharmaceutical Company Limited